Clinical trials: Antitumor Drug
Metastatic Cancer, Solid Tumor
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
This is the first study to test Sym022 in humans. The primary purpose of this study is to see if Sym022 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas…
- Conditions
- Metastatic Cancer, Solid Tumor, Lymphoma
- Trial name
- NCT03489369
- Testing
- Sym022
- Where
- 3 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Symphogen A/S
Endometrial Cancer
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
- Trial name
- NCT06463028
- Testing
- Sapanisertib, Serabelisib, Paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 40 people
- Sponsor
- Faeth Therapeutics
Rectal Cancer, Synchronous Liver Metastases
FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases
SYNCHRONOX is a multicenter cohort (retrospective then prospective) intending to include 550 patients with mid or low rectal adenocarcinoma (pMMR, T3-T4 and/or N+) and resectable synchronous liver metastases, treated upfront with…
- Conditions
- Rectal Cancer, Synchronous Liver Metastases, Antineoplastic Combined Chemotherapy Protocols, Surgical Therapy
- Trial name
- SYNCHRONOX (NCT07467434)
- Where
- France
- Volunteers
- 550 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cancer, Solid Tumor, Adult
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab.
- Conditions
- Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma
- Trial name
- KEYNOTE-E12 (NCT04443088)
- Testing
- INV-1120, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 78 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Leukemia, Chronic Myeloid, Myelodysplastic Syndromes
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Purpose There is a growing evidence of high efficacy of post-transplantation cyclophocphomide (PTCy)-based GVHD prophylaxis in haploidentical and matched related and unrelated bone marrow transplantation.
- Conditions
- Leukemia, Chronic Myeloid, Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
- Trial name
- NCT02627573
- Testing
- Unrelated allogeneic stem cell transplantation, Busulfan, Fludarabine monophosphate
- Where
- Russia
- Volunteers
- 32 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Breast Cancer, Ovarian Cancer
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer, PIK3CA Mutation
- Trial name
- NCT07524322
- Testing
- RGT-490
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- Regor Pharmaceuticals Inc.
Metastatic Breast Cancer
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer
- Trial name
- DB-07 (NCT04538742)
- Testing
- Trastuzumab deruxtecan, Durvalumab, Paclitaxel
- Where
- 72 sites in United States, Australia and 13 more
- Volunteers
- 245 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma, Fibrolamellar Hepatocellular Carcinoma
Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma
The purpose of this study is to evaluate the antitumor activity of sunitinib in patients with advanced/inoperable fibrolamellar hepatocellular carcinoma.
- Trial name
- Fibrolam (NCT01215565)
- Testing
- Sutent
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal
Avelumab in Refractory Testicular Germ Cell Cancer.
This is a proof-of-concept study to define efficacy of AVELUMAB in patients with multiple relapsed/refractory germ cell tumors (GCTs).
- Conditions
- Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal, Neoplasms, Testicular Diseases
- Trial name
- NCT03403777
- Testing
- Avelumab
- Where
- Slovakia
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute, Slovakia
Myelodysplastic Syndromes
Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)
The primary purpose of this study is to determine the effectiveness and safety of azacitidine in the treatment of Taiwanese subjects with higher-risk Myelodysplastic Syndrome (MDS).
- Trial name
- NCT01201811
- Testing
- Azacitidine
- Where
- 11 sites in Taiwan
- Volunteers
- 44 people
- Sponsor
- Celgene
Metastatic Solid Tumor, Colon Cancer
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
- Conditions
- Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
- Trial name
- INJECTABL-1 (NCT05688280)
- Testing
- 1.0% IP-001 for Injection
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- Immunophotonics, Inc.
Head and Neck Squamous Cell Carcinoma, Locally Advanced Rectal Cancer
GALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients
GALENOS 1 is a prospective observational study designed to explore longitudinal changes in nutritional status and body composition in patients with head and neck squamous cell carcinoma, locally advanced rectal cancer, and lung…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Locally Advanced Rectal Cancer, Lung Cancer
- Trial name
- GALENOS 1 (NCT07511413)
- Where
- Italy
- Volunteers
- 110 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Neoplasms
AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor
The purpose of this study is to determine the recommended dose of the combination of AVE8062 with platinum salts (cisplatin or carboplatin) and taxanes (docetaxel or paclitaxel) in patients with advanced solid tumors for which…
- Trial name
- NCT00719524
- Testing
- OMBRABULIN (AVE8062)
- Where
- 3 sites in France, Italy and 1 more
- Volunteers
- 71 people
- Sponsor
- Sanofi
MPN (Myeloproliferative Neoplasms)
Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
This is a Phase IV, multicenter, non-interventional, non-randomized, prospective, observational study in an adult population (patients >18 years old) of men and women who have been diagnosed with clinically overt PV and are being…
- Trial name
- NCT02252159
- Where
- 266 sites in United States, Puerto Rico
- Volunteers
- 2,544 people
- Sponsor
- Incyte Corporation
Drug-Induced Acute Liver Injury
Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury.
The clinical trial is designed to evaluate the efficacy of bicyclol for patients with antineoplastic drug-induced liver injury and investigate factors effecting the therapeutic outcome.
- Trial name
- NCT05711459
- Testing
- Bicyclol tablets
- Where
- China
- Volunteers
- 5,405 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Multiple Myeloma
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
The purpose of this study is to determine whether AT7519M alone or AT7519M plus bortezomib are effective treatments in patients with previously treated multiple myeloma.
- Trial name
- NCT01183949
- Testing
- AT7519M, Bortezomib
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Solid Tumors
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
The purpose of this first-in-human study, CTMX-904-101, is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-904 in adult subjects with metastatic or locally…
- Trial name
- NCT05387265
- Testing
- CX-904
- Where
- 5 sites in United States
- Volunteers
- 83 people
- Sponsor
- CytomX Therapeutics
Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor Cancer
A Study of MC001 in Patients With Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) and Other Folate Receptor Alpha (FRα)-Expressing Solid Tumors
The purpose of this First-in-Human, Phase 1 study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of MC001 in adults with advanced or…
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor Cancer, Metastatic Pancreatic Cancer, Metastatic Solid Tumors
- Trial name
- NCT07909356
- Testing
- MC001
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Medicovestor, Inc
Breast Cancer, Paclitaxel Adverse Reaction
Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.
This study looks into how a common breast cancer treatment, paclitaxel, can sometimes cause severe side effects that make it hard for patients to continue treatment.
- Conditions
- Breast Cancer, Paclitaxel Adverse Reaction, Chemotherapeutic Toxicity, Chemotherapeutic Agent Toxicity
- Trial name
- PABTOX (NCT06387901)
- Testing
- Paclitaxel Chemotherapy
- Where
- 2 sites in Belgium
- Volunteers
- 40 people
- Sponsor
- Universitair Ziekenhuis Brussel
Urinary Bladder Neoplasms, Urologic Neoplasms
Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)
This study is a single-arm, open-label, single-center study to assess the safety of tislelizumab with BCG, and to obtain the preliminary efficacy results in subjects who have been diagnosed with high-risk NMIBC without prior BCG…
- Conditions
- Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Antineoplastic Agents
- Trial name
- TACBIN-01 (NCT04922047)
- Testing
- tislelizumab and BCG
- Where
- China
- Volunteers
- 6 people
- Sponsor
- RenJi Hospital